Latest Insider Transactions at Cue Biopharma, Inc. (CUE)
This section provides a real-time view of insider transactions for Cue Biopharma, Inc. (CUE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cue Biopharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cue Biopharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 25
2023
|
Anish Suri PRESIDENT AND CSO |
BUY
Open market or private purchase
|
Direct |
4,000
+2.86%
|
$8,000
$2.76 P/Share
|
|
Aug 14
2023
|
Daniel R Passeri CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
3,000
+2.18%
|
$6,000
$2.86 P/Share
|
|
Mar 23
2023
|
Peter A Kiener |
SELL
Open market or private sale
|
Direct |
9,325
-96.31%
|
$27,975
$3.28 P/Share
|
|
Mar 23
2023
|
Peter A Kiener |
BUY
Exercise of conversion of derivative security
|
Direct |
9,682
+50.0%
|
$19,364
$2.86 P/Share
|
|
Aug 22
2022
|
Kerri Ann Millar CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,828
-16.5%
|
$8,484
$3.05 P/Share
|
|
Aug 21
2022
|
Kerri Ann Millar CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+28.01%
|
-
|
|
Jun 14
2022
|
Cameron Gray Director |
SELL
Payment of exercise price or tax liability
|
Direct |
51,562
-6.98%
|
$154,686
$3.2 P/Share
|
|
Jun 14
2022
|
Cameron Gray Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
61,111
+7.64%
|
$122,222
$2.7 P/Share
|
|
May 27
2022
|
Frank Morich |
BUY
Open market or private purchase
|
Direct |
28,000
+50.0%
|
$84,000
$3.75 P/Share
|
|
May 24
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
55,000
+5.53%
|
$165,000
$3.34 P/Share
|
|
May 23
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
150,000
+14.49%
|
$450,000
$3.52 P/Share
|
|
Mar 31
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
735,000
+50.0%
|
$2,940,000
$4.76 P/Share
|
|
Mar 31
2022
|
Daniel R Passeri CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Direct |
10,000
-7.06%
|
-
|
|
Mar 31
2022
|
Daniel R Passeri CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
32,122
-18.49%
|
$128,488
$4.88 P/Share
|
|
Mar 31
2022
|
Daniel R Passeri CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+30.16%
|
-
|
|
Mar 31
2022
|
Anish Suri PRESIDENT AND CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,068
-6.38%
|
$28,272
$4.88 P/Share
|
|
Mar 31
2022
|
Anish Suri PRESIDENT AND CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,668
+13.09%
|
-
|
|
Nov 16
2021
|
Peter A Kiener |
SELL
Open market or private sale
|
Direct |
1,361
-100.0%
|
$24,498
$18.02 P/Share
|
|
Nov 16
2021
|
Peter A Kiener |
BUY
Exercise of conversion of derivative security
|
Direct |
1,361
+50.0%
|
$2,722
$2.86 P/Share
|
|
Nov 15
2021
|
Anish Suri PRESIDENT AND CSO |
SELL
Open market or private sale
|
Direct |
8,000
-7.84%
|
$144,000
$18.05 P/Share
|
|
Nov 15
2021
|
Anish Suri PRESIDENT AND CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+7.27%
|
$64,000
$8.26 P/Share
|
|
Nov 15
2021
|
Peter A Kiener |
SELL
Open market or private sale
|
Direct |
18,815
-100.0%
|
$319,855
$17.92 P/Share
|
|
Nov 15
2021
|
Peter A Kiener |
BUY
Exercise of conversion of derivative security
|
Direct |
18,815
+50.0%
|
$37,630
$2.86 P/Share
|
|
Nov 11
2021
|
Anish Suri PRESIDENT AND CSO |
SELL
Open market or private sale
|
Direct |
20,000
-17.54%
|
$300,000
$15.07 P/Share
|
|
Nov 11
2021
|
Anish Suri PRESIDENT AND CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+14.92%
|
$120,000
$6.42 P/Share
|
|
Oct 06
2021
|
Anish Suri PRESIDENT AND CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,134
-13.07%
|
$169,608
$12.97 P/Share
|
|
Oct 03
2021
|
Anish Suri PRESIDENT AND CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,334
+23.56%
|
-
|
|
Oct 01
2021
|
Kerri Ann Millar CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,251
-10.67%
|
$17,514
$14.21 P/Share
|
|
Oct 01
2021
|
Kerri Ann Millar CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,251
+9.64%
|
$8,757
$7.5 P/Share
|
|
Sep 30
2021
|
Daniel R Passeri CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
31,677
-24.3%
|
$443,478
$14.57 P/Share
|
|
Sep 30
2021
|
Daniel R Passeri CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+36.52%
|
-
|
|
Sep 24
2021
|
Daniel R Passeri CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
3,400
+5.78%
|
$47,600
$14.72 P/Share
|
|
Sep 23
2021
|
Anish Suri PRESIDENT AND CSO |
SELL
Open market or private sale
|
Direct |
20,000
-21.09%
|
$300,000
$15.23 P/Share
|
|
Sep 23
2021
|
Anish Suri PRESIDENT AND CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+17.42%
|
$120,000
$6.42 P/Share
|
|
Aug 23
2021
|
Kerri Ann Millar CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,961
-15.77%
|
-
|
|
Aug 23
2021
|
Kerri Ann Millar CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+34.91%
|
-
|
|
Mar 16
2021
|
Kenneth Pienta Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
439
-18.0%
|
$6,585
$15.09 P/Share
|
|
Mar 16
2021
|
Kenneth Pienta Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
439
+15.25%
|
$2,195
$5.0 P/Share
|
|
Mar 15
2021
|
Kenneth Pienta Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,000
-86.67%
|
$195,000
$15.1 P/Share
|
|
Mar 15
2021
|
Kenneth Pienta Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,000
+46.43%
|
$65,000
$5.0 P/Share
|
|
Feb 17
2021
|
Kenneth Pienta Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,274
-68.12%
|
$64,110
$15.05 P/Share
|
|
Feb 17
2021
|
Kenneth Pienta Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,274
+30.19%
|
$12,822
$3.93 P/Share
|
|
Feb 16
2021
|
Kenneth Pienta Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
16,000
-88.89%
|
$240,000
$15.15 P/Share
|
|
Feb 16
2021
|
Kenneth Pienta Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+47.06%
|
$32,000
$2.86 P/Share
|
|
Jan 20
2021
|
Kenneth Pienta Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,720
+36.56%
|
$40,800
$15.07 P/Share
|
|
Nov 24
2020
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Direct |
6,548
+3.82%
|
$78,576
$12.64 P/Share
|
|
Oct 05
2020
|
Anish Suri PRESIDENT AND CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,800
-14.43%
|
$156,800
$16.3 P/Share
|
|
Oct 03
2020
|
Anish Suri PRESIDENT AND CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,333
+32.93%
|
-
|
|
Sep 30
2020
|
Cameron Gray Director |
BUY
Open market or private purchase
|
Direct |
5,000
+0.73%
|
$75,000
$15.3 P/Share
|
|
Sep 29
2020
|
Cameron Gray Director |
BUY
Open market or private purchase
|
Direct |
5,000
+0.74%
|
$75,000
$15.0 P/Share
|